Willebrand factor, as well as one or more plateletagglutinating factors, have been implicated in the pathogenesis of TTP. But, the actual mechanisms of platelet agglutination have not been satisfactorily explained. Recent studies suggested the 37-kDa platelet-agglutinating protein (PAP) p37 to be partially responsible for the formation of platelet thrombi in patients with TTP. We studied mobility in SDS-PAGE, the sequence of N-terminal amino acid residues, DNA and antigenic characteristics of PAP p37, which might be related to the pathogenesis of TTP. PAP p37 was purified from the plasma of a 31-year-old male Korean patient with acute TTP. The findings are as follows: (1) We compared PAP p37 with thrombin through the use of SDS-PAGE, either with or without β-mercaptoethanol. PAP p37 did not appear to be cleaved between the A-and B-chains of prethrombin 2. However, thrombin did cleave between those of prethrombin 2, but linked with disulfide bridge.
Introduction
Thrombotic thrombocytopenic purpura (TTP) was first described by Moschcwitz in 1924 (Moschcowitz, 1924) . It was characterized by the fluctuating-neurologic symptom, thrombocytopenia, microangiopathic hemolytic anemia, fever, and renal dysfunction that was rapidly fatal because of the involved organ dysfunction. Typical pathologic features of this disorder are widespread hyaline thrombi within the vessel wall. In the involved organ, a hyaline material that principally consists of platelet thrombi occludes terminal arterioles and capillaries. Microvascular occlusions are seen in most organs, including the lungs and eyes. The most-frequently-involved organs are the brain, heart, spleen, kidneys, pancreas, and adrenals. These hyaline thrombi consist of plateletagglutination with little fibrin, which differs from thrombi that consists of platelet-aggregation with rich fibrin that is shown in common pathways of coagulation, due to endothelial cell injury (Moschcowitz, 1924) .
The pathogenesis of TTP is still unknown. Recent suggestions are that persisting-endothelial-derived multimeric von Willebrand factor (vWF), or unusually large vWF, which cannot be cleaved normally (Wagner et al., 1995; Tsai and Lian, 1998; Veyradier et al., 2001) , and 37 kDa plateletagglutinating protein (PAP), p37, are associated with these pathologic mechanisms (Lian et al., 1979 (Lian et al., , 1991 Siddiqui and Lian, 1985 , 1993 Jin et al., 1995; Chen S and Lian 1998) . Other investigators reported that there were reduced prostacyclin I 2 (PG I 2 ) production (Wu KK, 1992) , or *To whom correspondence should be addressed. Tel: 82-32-340-2114 , Fax: 82-32-340-2669 defections of the plasma-binding ability of PG I 2 (Wu KK et al., 1985) in TTP. The causes of multimeric or unusually large vWF production in TTP have been reported. These are associated with the deficiency of the vWF-cleaving protease, or the formation of an antibody against the protease (Tsai and Lian, 1998; Tsai et al., 2000) . On the other hand, PAP p37 was found in the plasma of TTP patients, which are known to have potent platelet-agglutination activity that was first described by Siddiqui and Lian (Siddiqui and Lian, 1985) .
We isolated and purified the platelet-agglutinating protein, PAP p37, from a 31-yr-old Korean male patient with acute TTP, and studied the characteristics of the PAP p37 (Kim et al., 1992; Jin et al., 1995) . This was similar to most of the chemical characteristics of PAP p37 that are described by Siddiqui and Lian (Siddiqui and Lian, 1985 , 1993 , except for the weak binding activity to concanavalin A (Con-A). PAP p37 has a molecular weight of 37 kDa, as well as single polypeptide of acid glycoprotein with potent plateletagglutinating activity.
Only a few of the chemical characteristics of PAP p37 are presently known. Therefore, we studied the characteristics of PAP p37, which might be the pathogenesis of TTP.
Materials and Methods

Purification of PAP p37
We used the plasma that was obtained during plasmapheresis of a 31-yr-old Korean patient with acute TTP (Kim et al., 1992) . Clinical manifestation, laboratory data, pathologic features, and a platelet-agglutination test confirmed the diagnosis of TTP. Two liters of the plasma were directly lyophilized and stored at −70 o C until use. The purification method for PAP p37 was the same as the previous report (Jin et al., 1995) . All of the procedures were performed at 4 o C. Briefly, PAP p37 was purified from the resolved lyophilized plasma in a 10 mM Tris-HCl pH 7.4 buffer by ammonium sulfate fractionation, DEAE-Sephacel, and Con-ASepharose chromatographies, as previously described (Siddiqui and Lian, 1985) . The fraction with maximum-agglutinating activity was eluted by a linear gradient of α-methyl-D-glucoside (0-0.5 M) from a Con A -Sepharose column. The partially-purified PAP p37 was further purified by performing a Superose 12 gel filtration on fastperformance liquid chromatography (FPLC). The PAP p37 fraction after Con-A-Sepharose chromatography was collected, then dialyzed against 20 mM Tris-HCl (pH 7.4) that contained 0.1 M NaCl and concentrated by ultrafiltration with a YM-10 membrane (Amicon Inc., Beverly, USA). The concentrated sample was loaded onto Superose 12 (2.5 × 30 cm) on FPLC that was previously equilibrated with the Tris-saline buffer (pH 7.4), and developed with the same buffer at a flow rate of 0.3 ml per min (Jin et al., 1995) .
Measurement of platelet agglutination
The platelet-rich human plasma from normal subjects was prepared from freshly-collected blood by 3.8% sodium citrate and subsequently centrifuged at 180 g for 10 min at room temperature, as previously described (Lian et al., 1979) . Platelet washing was carried out using the albumin density-gradient method (Walsh et al., 1977) . Next, 0.1 ml of the washed-platelet suspension that contained 7 × 10 8 platelets/ml in a Tris-saline buffer (pH 7.4) was prewarmed at 37 o C for 5 min. The platelet agglutination was initiated by adding 0.4 ml of the samples that were collected during the purification of PAP p37, and measured by recording the light transmission changes at 609 nm using a Chrono-log aggregometer (Haverstown, USA). Lighttransmission values were converted to percent agglutination, as previously described (Siddiqui and Lian, 1985) . N-terminal amino acid sequencing of PAP p37 About 1-2 nM of the highly-purified PAP p37 (as judged by SDS-PAGE) in 30 ul distilled water was bottled onto a fiberglass peptide disk in the sample cartridge of a Porton 2090 E automatic protein sequencer (Beckman Co, Fullerton, USA). Amino acids were separated by an on-line HPLC and quantitated from their peak areas using standard procedures. The N-terminal sequence that contained 21 amino acids was analyzed using a Sequence Homology analysis of NCBI BLAST from http://www.ncbi.nlm.nih.gov/BLAST1 and Multiple Sequence Alignment of GeneDoc 2.6.0 from http://www.psc.edu/ biomed/genedoc/.
Enzyme-linked immunosorbent assay (ELISA)
Each well of the polystyrene microtiter plates (Plastomed, Warsaw, Poland) that contained 96 wells was coated with either the purified PAP p37 or thrombin in a 0.1 M carbonate/bicarbonate buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 , pH 9.6, 0.02% NaN 3 ). Unoccupied binding sites were blocked by 2% BSA in TBS (100 mM tris-HCl buffer, pH 7.4, containing 1.5 M NaCl). The plates were sequentially incubated with mouse IgG-horseradish peroxidase conjugate (IgG-HRP; Sigma Co, St. Louis, USA) for 3 h at 37 o C each with gentle shaking. After the excess conjugate was removed by washing with TBS, then 4-chloro-1-naphthol (Sigma Co, St. Louis, USA) was added to the reaction mixtures, and the reaction was followed by increases in absorbance at 492 nm and comparison with a standard peroxidase reaction. For competitive ELISA, the wells were coated with 100 ul (1 ug/ml) of the carbonate buffer that contained either the purified PAP p37 or thrombin, then incubated with the mouse anti-human thrombin antibody that was premixed with increasing concentrations of the purified PAP p37 before adding the IgG-HRP conjugate.
DNA sequence analysis of the prothrombin gene in the patient with TTP Genomic DNA was isolated from the blood of the same TTP patient, according to the procedure of Degen (Degen et al, 1983; Degen and Davie, 1987) . In order to examine the possibility that PAP p37 may be derived from a mutated prothrombin gene, an interesting region (including exons 8 and 9) was amplified by PCR using two oligonucleotides, 5'-ATG GGT GAG GAA TGG CCC AG-3' and 5'-GTC ATC TGT AAA GCC CAG GC-3'. Each cycle included 1 min at 94 o C for denaturation, 1 min at 58 o C for annealing, and 2 min at 72 o C for extension. Following 30 cycles, 3 min for the extension was allowed to complete the PCR reaction. The amplified PCR product was cloned into a T-vector (Amersham, Buckinghamshire, UK) and the insert was sequenced using a CircumVent thermal cycle DNA sequencing kit (New England Biolabs, Hertfordshire, UK) according to the procedures that were supplied by the company.
Other methods SDS-PAGE was performed in a small vertical slab gel unit (Bio-Rad instruments, Herculis, USA) with samples that were heated at 90 o C for 1 min, as described by Laemmli (Laemmli, 1970) . The protein was determined according to Lowry using BSA as a standard (Lowry et al., 1951) .
Results
The characteristics of PAP p37 The characteristics of purified PAP p37 from the plasma of a patient with TTP were the same as the PAP p37 that was described by Siddiqui and Lian (Siddiqui and Lian, 1985) , except for the elution differences among the Con A-Sepharose column linear gradients. In our experiment, PAP p37 was tightly bound to Con A (0-0.5 M, Con A-I, -II), especially Con A-II (0.5 M), although less eluted in the presence of a high concentration (1 M, Con A-III) of α-methyl-D-glucoside (Siddiqui and Lian, 1985) (Fig. 1) . The proteins from Con A-I and -II had potent platelet-agglutinating activity, but the protein from the third peak (Con A-III) showed no significant platelet-agglutinating activity. This indicates that these two glycoproteins may be slightly different in terms of carbohydrate composition. During further purification, the forth-purified peak (Fig. 2-A , Super-IV) protein on FPLC appeared to migrate as a single band on SDS-PAGE (Fig. 2-B , lanes 5 and 6, fractions 86 and 91), indicating that it was isolated in a homogeneous state. This Super-IV fraction revealed potent platelet agglutination (Fig. 3-A) . This activity was inhibited when the fraction was preincubated with normal plasma (Fig. 3-B) . The purified PAP p37 was determined to be a glycoprotein by Schiffs basestaining (not shown); it was confirmed as an acidic protein with an isoelectric point (pI) of 4.7 by isoelectric focusing (Fig. 4) . N-terminal amino acid sequence of purified PAP p37 is identical to 285-305 amino acid sequences of prepro prethrombin and prethrombin 2. The N-terminal sequence of PAP p37 was T-
which was determined by the automatedEdman-degradation method. The sequence is identical to that established for 285-305 amino acid residues of human prothrombin and prethrombin 2 (Degen and Davie, 1987) (Fig. 5) . The 9th amino acid (X) was ambiguous, but was suggested to be glyco-amino acid or cysteine by comparing a previous prothrombin amino acid sequence (Degen and Davie, 1987) . This amino acid is a binding site of the catalytic domain for forming the prothrombin tertiary structure. The Thr285 of prothrombin is the first amino acid sequence of the human prothrombin light chain by the successive proteolytic cleavages for prothrombin activation (Lian et al., 1991) . PAP p37 was identical to this amino acid sequence of a part of the prothrombin (B-chain of prethrombin 2), or the a-thrombin light chain of its cleavage product. Human thrombin is composed of two polypeptides, a light chain of 6 kDa and a heavy chain of 31 kDa (Mann et al., 1994) . 
SDS-PAGE with or without β-mercaptoethanol
Because PAP p37 was identical with a portion of prothrombin that contained the A-and B-chains (37 kDa), we studied its characteristics. We discovered that PAP p37 appeared to be the same size polypeptide band on SDS-PAGE, both in the presence (reducing condition) and absence (unreducing condition) of β-mercaptoethanol; the normal human α-thrombin appeared as two different peptide bands in these conditions (Fig. 6) . This was an interesting and important result for analogizing PAP p37. PAP p37 has a similar A shows the agglutination by the purified PAP: 0.4 ml (about 1 ug) of the purified PAP was added to the 0.1 ml of washed human-platelet suspension in a Tri-saline buffer (pH 7.4) that was prewarmed at 37 o C for 5 min. B is the inhibition of PAPinduced platelet-agglutination by normal plasma, respectively: 0.1 ml of the platelet suspension was preincubated with 0.3 ml of either normal plasma and 0.1 ml of the PAP was added to mixture. The percent agglutination of platelets was determined using a Chrono-log aggregometer. Fig. 4 . Isoelectric pH of the purified PAP. The pI value of PAP was determined by isoelectric focusing electrophoresis. The arrow indicates PAP with a pI value of 4.7. molecular weight (37 kDa) as prethrombin 2 and thrombin. But in thrombin, the A-and B-chains are already cleaved by Xa, which was only linked by the disulfide bond that can be separated in the presence of β-mercaptoethanol into the Aand B-chains. Therefore, two different bands were revealed in SDS-PAGE, with or without β-mercaptoethanol. PAP p37 appeared to be the same-sized band in SDS-PAGE with or without treating β-mercaptoethanol. With these findings, we could conclude that PAP p37 is similar to prethrombin 2. When prothrombin cleaved between fragment 1.2 and the Achain, then the prethrombin 2 joined A-B chains were produced (Fig. 7) .
Enzyme-linked immunosorbent assay (ELISA)
The binding activity of PAP p37 to anti-thrombin was similar to thrombin ( Fig. 8-A) . Two proteins, PAP p37 and thrombin, are suggested to have similar antigenicity from the results of their competitive binding ability to the anti-thrombin antibody (Fig.  8-B) .
DNA sequence analysis of the prothrombin gene
To identify the gene mutation that causes PAP p37 production, the DNA sequence of the prothrombin gene was analyzed. The exon 8 and 9 regions of the prothrombin gene (including the part of interest) were amplified by a polymerase chain reaction with the genomic DNA from the patients blood cells as a template. The DNA sequence of the amplified PCR product did not reveal any mutation in the regions of the prothrombin gene. Therefore, it was shown that PAP p37 is not a mutant product of the prothrombin gene, but an unsuccessfully-cleaved product of prothrombin through the proteolysis process.
Discussion
PAP p37 has potent platelet-agglutinating activity in the patients with TTP that were first described by Siddiqui and Lian (Siddiqui and Lian, 1985 , 1993 . We found and reported the partial chemical characteristics of the Korean Fig. 5 . Amino acid sequence and tentative structure for prepro prothrombin showing the location of the 13 intervening sequences (A-M). The prepro leader sequence is removed during the biosynthesis of the protein by signal peptidase, a protease that hydrolyzes, and R-A peptide bond between −1 and 1. The Gla domain and two kringle structures are located in the amino-terminal region of the protein that is removed after proteolytic activation by factor Xa (*). Thrombin is composed of a light chain (49 amino acids) that is linked to a catalytic domain (259 amino acids). Thrombin undergoes further self-autolysis by removing 13 amino acids (from T-272 to R-284) from the N-terminal of the light chain (T-285 to E-305 of N-terminal amino acid of prothrombin is exactly the same as the sequence of 21 N-terminal amino acid sequence of PAP). The amino acids that participate in catalysis are circled (H-43, D-99, and S-205) . Solid diamonds represent the three carbohydrate attachment sites. The positions of the intervening sequences are indicated. The amino acid residues are numbered as follows, beginning with the amino-terminal end: prepro leader sequence, −43 to −1; prothrombin fragment 1, 1-271; light chain of thrombin, 1-49; catalytic chain of thrombin, 1-259. The Asn at position 121 is coded by an AAC codon in the cDNA (Degen et al., 1983) , while an ACC at this position in the gene codes for a Thr. type PAP p37 that was similar to the previous-reported PAP p37, except for the weak Con-A binding activity (Jin et al., 1995) . Compared to its important role in the pathogenesis of TTP, however, only some of the protein properties of PAP p37 are known. Studies about its basic structure are presently minimal.
In this study, it was noteworthy that the N-terminal amino acid sequence of PAP p37 is identical to 285-305 amino acid sequences of the prothrombin fragment and prethrombin 2. This may provide a clue to the pathogenesis of TTP. Prothrombin or the coagulation factor II, one of the hepaticderived vitamin K-dependent procoagulants (coagulation factors II, VII, IX, and X), are the substrate for the thrombin formation by the activated factor X (Xa) in the common pathway and procoagulant itself, which participates in the platelet-agglutination. The entire amino acid sequence of prothrombin has been determined (Degen et al., 1987) . Prothrombin is a single-chain glycoprotein with a molecular weight of 72 kDa. The glutamate residue (Gla domain) and 2 kringle structures are located in the amino-terminal region of the prothrombin that is removed after proteolytic activation by factor Xa. The carboxy-terminal portion is composed of a light chain that is linked to a catalytic domain that contains serine protease of the proteolytic-thrombin function (Fig. 5) . After the glutamate residue is carboxylated in the presence of vitamin K, additional binding of the calcium and phospholipid and proteolysis by Xa follows. The first cleavage of prothrombin by Xa occurs by two pathways as follows: (1) Prothrombin fragments 1, 2, or 3 in N-terminal and prethrombin 2, which consists of the A and B chains. (2) The intermediate products of prothrombin cleavage, meizothrombin, which is cleaved between the A and B chains and bridged by a disulfide bond (Kisiel et al., 1974; Walz et al., 1974; Butkowski et al., 1977) (Fig. 7) . If the first cleavage site of prothrombin is between the A chain (inhibiting B chain protease action) and the B chain (with serine protease action (meizothrombin)), then it is linked by a disulfide bond, and the proteolytic activation of the B chain is initiated by removing fragments 1, 2 in the N-terminal portion, and then generating active α-thrombin (Walz et al., 1974; Butkowski et al., 1977) . However, if prothrombin is initially cleaved by Xa to the prothrombin fragments 1, 2 and prethrombin 2, then the union of the A and B chains persisted and prethrombin 2 (inactive thrombin light chain) accumulated in the plasma. The accumulated-procoagulant, prethrombin 2, binds to glycoprotein IV (GP IV) of the platelet membrane and exaggerates platelet agglutination (Lian et al., 1991; Siddiqui Fig. 6 . Comparison of electrophoretic mobility between PAP and thrombin under non-reducing and reducing condition. Human thrombin (lanes 1 and 2) and purified PAP (lanes 3 and 4) were electrophoresed in the absence (lanes 1 and 3) and presence (lanes 2 and 4) of β-mercaptoethanol. Fig. 7 . Products of prothrombin proteolysis by factor Xa and thrombin. Factor Xa-catalyzed proteolysis produces the prothrombin fragment 1.2 and thrombin. Two intermediate reaction products can either be observed (prethrombin 2) or inferred as necessary to account for the rate of production of thrombin from prothrombin (meizothrombin). Thrombin-catalyzed cleavage produces the separate fragments 1 and 2 from the fragment 1.2. and Lian, 1992; Jin et al., 1995) . Therefore, vascular occlusion by the platelet agglutination leads to tissue necrosis and disseminated-intravascular coagulation by released tissue factors.
From our study, there was no evidence that prethrombin 2 was the mutant product of the prothrombin gene from the DNA sequence analysis. There is more than one normal cleavage site of prothrombin (Rabiet et al., 1986) . The formation of fragments 1,2 and prethrombin 2 in any case exceed the production of meizothrombin, which participates in active thrombin formation; the accumulation of prethrombin 2 seems to make platelet agglutination. This process may be related to the pathogenesis of TTP, but needs further evaluation. The cause of the enhanced prethrombin 2 production in TTP is unclear. Recent studies revealed that the defect or antibody formation against the proteolytic enzyme generated multimeric or usually large vWF in TTP (Wagner et al., 1995; Tsai and Lian, 1998) . With the same mechanism, the accumulation of prethrombin 2 can be caused by the unusual proteolysis of prothrombin, which may be related with proteolysis inhibitors, antibody, or quantitative or qualitative defects of proteolytic enzymes (Koo et al., 2000; Bae et al., 2001) . With this result, we can postulate that there are multiple proteolytic defects that are due to proteolytic enzyme deficiency and/or presence of proteolytic enzyme inhibitors, not only vWF, but also other procoagulants in TTP. This can be the answer to the infusion of normal plasma for the dilution of inhibitors, and the source of proteolytic enzymes and plasma exchange for the removal of proteolytic enzyme inhibitors that are effective in TTP treatment. Further study will be necessary (George, 2000; Rock, 2000) . The competitive binding of prethrombin 2 to the anti-thrombin antibody with thrombin suggests an antigenic similarity in both proteins. But, prethrombin 2 had no typical thrombin function that would convert fibrinogen to fibrin, because it was not influenced by the thrombin inhibitor, such as hirudin or heparin (data not shown). As previously mentioned, PAP p37 that has potent platelet-agglutinating activity in TTP has similar characteristics to prethrombin 2 that unsuccessfully cleaved the thrombin light chain.
Data presented in this study showed that PAP p37 has similar characteristics to prethrombin 2, inactivated thrombin light chain. This is due to the result of no cleaved disulfide bond between the A and B chains. This product is due to the unsuccessful cleavage of prothrombin. We anticipate that this pact can be helpful in evaluating the pathogenesis of TTP. The possibility of using the recombinant proteolytic enzyme in TTP treatment and abnormal proteolysis (related to the production of multimeric or unusually large vWF and prethrombin 2 that can be a common pathogenesis of TTP) should be studied more. The 96 wells that were coated with varying concentrations of either PAP (:) or thrombin (;) were incubated with the anti-thrombin antibody; the bound antibody was detected using the enzyme-conjugated secondary antibody (IgG-HRP) and a chromogenic substrate (4-chloro-naphthol), and quantitated by taking absorbencies at 492 nm. B; The plates were coated with 1 mg/ml of either PAP (:) or thrombin (;). Then, the anti-thrombin antibody that was mixed with increasing concentrations of PAP were added. The plate-bound antibody was similarly detected. The absorbance value in absence of PAP was set to 100% binding. Then, the absorbance value in presence of PAP was converted to percent binding.
